Deals In Depth: January 2022

Executive Summary

Ten $1bn+ alliances were penned in January. Topping the list was a potential $5.2bn deal between Sanofi and Exscientia for the development of up to 15 novel small molecule candidates across oncology and immunology. The collaboration will leverage Exscientia’s AI-driven personalized medicine platform which enables a “patient-first” approach through integrating primary human tissue samples into early target and drug discovery research. Exscientia will lead small molecule drug design and lead optimization activities up to development candidate nomination, with Sanofi assuming responsibility for preclinical and clinical development, manufacturing and commercialization.